After completing his Master studies in Biotechnology, Mohit worked as a Junior Research Fellow at the International Center for Genetic Engineering and Biotechnology (ICGEB), New Delhi in the Recombinant Gene Products lab led by Dr. Navin Khanna. He moved to Würzburg, Germany to pursue his PhD in the lab of Prof. Hermann Schindelin where he worked at the apex of the ubiquitylation pathway exploring the structure-function relationship of the ubiquitin-activating enzymes (E1, Uba1, Uba6) and its interactions with multiple E2 enzymes. In addition, he established the structural basis of the variable potencies of adenosyl sulfamate inhibitors towards Uba1 which hold promise for cancer therapy. After a brief postdoc in Würzburg, he moved to Frankfurt to join the Dikic lab to pursue his fascination for novel chemistry of ubiquitylation discovered in Legionella. In May 2020, he started as a Team leader with EUbOPEN IMI/ SGC Frankfurt to target the ubiquitin system with new probes as therapeutics for human diseases. Since 2025, Mohit is serving as Proxidrugs PI, exploring the modalities of induced proximities such as protein degradation. In addition, he is heading the protein production facility in Frankfurt Competence Center of Emerging Therapeutics (FCET).